孟鲁司特钠联合丙卡特罗和阿奇霉素治疗支原体肺炎合并哮喘急性发作患儿的效果

Effects of Montelukast sodium combined with Procaterol and Azithromycin in treatment of children with mycoplasma pneumonia complicated with acute attack of asthma

目的:观察孟鲁司特钠联合丙卡特罗和阿奇霉素治疗支原体肺炎合并哮喘急性发作患儿的效果。方法:选取2022年2月至2023年6月该院收治的150例支原体肺炎合并哮喘急性发作患儿进行前瞻性研究,按照随机数字表法分为研究组与对照组各75例。对照组采用丙卡特罗联合阿奇霉素治疗,研究组在对照组基础上加用孟鲁司特钠片治疗,比较两组治疗总有效率、炎性指标[C反应蛋白(CRP)、降钙素原、白细胞计数(WBC)]水平、哮喘控制测试(ACT)评分、肺功能指标[第1秒用力呼气容积(FEV_(1))、FEV_(1)/用力肺活量(FVC)]水平、止咳时间、退热时间、肺啰音消失时间和不良反应发生率。结果:研究组治疗总有效率为92.00%,高于对照组的80.00%,差异有统计学意义(P<0.05);治疗后3 d,研究组ACT评分、FEV_(1)水平、FEV_(1)/FVC水平高于对照组,CRP、降钙素原、WBC水平低于对照组,差异均有统计学意义(P<0.05);研究组止咳时间、退热时间和肺啰音消失时间均短于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:孟鲁司特钠联合丙卡特罗和阿奇霉素治疗支原体肺炎合并哮喘急性发作患儿可提高治疗总有效率、ACT评分和肺功能指标水平,缩短止咳时间、退热时间和肺啰音消失时间,降低炎性指标水平,效果优于单纯丙卡特罗和阿奇霉素治疗。

Objective:To observe effects of Montelukast sodium combined with Procaterol and Azithromycin in treatment of children with mycoplasma pneumonia complicated with acute attack of asthma.Methods:A prospective study was conducted on 150 children with mycoplasma pneumonia complicated with acute attack of asthma admitted to the hospital from February 2022 to June 2023.They were divided into study group and control group according to the random number table method,75 cases in each group.The control group was treated with Procaterol combined with Azithromycin,while the study group was treated with Montelukast sodium tablets on the basis of those of the control group.The total effective rate of treatment,the inflammatory factor[C-reactive protein(CRP),procalcitonin,white blood cell count(WBC)]levels,the asthma control test(ACT)score,the lung function indexes[forced expiratory volume in one second(FEV_(1)),FEV_(1)/forced vital capacity(FVC)]levels,the cough relieving time,the fever relieving time,the lung rale disappearance time,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 92.00%,which was higher than 80.00%in the control group,and the difference was statistically significant(P<0.05).Three days after treatment,the ACT score,the FEV_(1) level and the FEV_(1)/FVC level in the study group were higher than those in the control group,the levels of CRP,procalcitonin and WBC were lower than those in the control group,and the differences were statistically significant(P<0.05).The cough relieving time,the fever relieving time,the lung rale disappearance time in the study group were shorter than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Montelukast sodium combined with Procaterol and Azithromycin in the treatment of the children with mycoplasma pneumonia complicated with acute attack of asthma can improve the total effective rate of treatment,the ACT scores and the lung function index levels,shorten the cough relieving time,the fever relieving time and the lung rale disappearance time,and reduce the levels of inflammatory factors.Moreover,it is superior to single Procaterol and Azithromycin treatment.